canine

(redirected from canine cognitive dysfunction syndrome)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • all
  • noun
  • adj

Synonyms for canine

one of the four pointed conical teeth (two in each jaw) located between the incisors and the premolars

any of various fissiped mammals with nonretractile claws and typically long muzzles

of or relating to a pointed conical tooth

Synonyms

of or relating to or characteristic of members of the family Canidae

References in periodicals archive ?
and Canada, Anipryl(R) is approved in Australia, New Zealand and Brazil for the treatment of canine Cognitive Dysfunction Syndrome and canine Cushing's disease.
1 million based on receipt of regulatory approvals for Canine Cognitive Dysfunction Syndrome (CDS) and Cushing's disease in specified countries.
Near-Term Revenue and Earnings Growth - arising from Anipryl(R) revenues following Pfizer's launch of this drug for the control of clinical signs associated with canine Cognitive Dysfunction Syndrome and the commencement of Pfizer's direct-to-consumer marketing campaign in February 1999, the recent Canadian launch of Alertec(TM) the first new treatment for narcolepsy in 40 years, 1999 launches of at least two Elan neurology products and increasing third party contract manufacturing business for DRAXIS Pharma.
Pursuant to this agreement, the receipt of FDA clearance of Anipryl(r) for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) on December 11, 1998, entitled DRAXIS to receive a US$10 million milestone payment from Pfizer and the receipt of clearance of Anipryl(r) from the National Registration Authority (NRA) in Australia for the control of clinical signs associated with canine CDS and Cushing's disease on December 14, 1998, entitled DRAXIS to receive a US$3 million milestone payment from Pfizer.
NYSE:PFE), has been cleared by National Registration Authority (NRA) for the control of clinical signs associated with canine Cognitive Dysfunction Syndrome (CDS) and for the control of clinical signs associated with uncomplicated canine pituitary-dependent hyperadrenocorticism (PDH or Cushing's disease).
Full browser ?